by mpzzqmvj | Apr 20, 2021 | Press Releases
FDA feedback supports Company’s Phase 2 development strategy for Alzheimer’s disease asset; IND filing on track for H2 2021 GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a...
by mpzzqmvj | Mar 25, 2021 | Press Releases
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement in at least 2 domains of the 17-domain NPC Severity Scale Trial data suggest that Trappsol® Cyclo™ overcomes the NPC1 defect by...
by mpzzqmvj | Mar 15, 2021 | Press Releases
– Multiple value-driving milestones expected throughout 2021- Trappsol® Cyclo™ Niemann Pick Disease Type C (NPC) clinical program on track to imminently report topline results from Phase 1/2 study- Company expects to commence enrollment in pivotal...
by mpzzqmvj | Mar 12, 2021 | Press Releases
Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer ProductsGAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical...
by mpzzqmvj | Mar 10, 2021 | Press Releases
Preeminent biotechnology commercialization leader with over 33 years of industry experience, including 16 years at Genentech with a pivotal role in commercializing products across multiple therapeutic areasGAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq:...
by mpzzqmvj | Mar 9, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
